Novo has co-led a series B round together with Omega Funds for Morphic Therapeutic, based on research by Harvard professor Timothy Springer.

US-based biotechnology developer Morphic Therapeutic closed an $80m series B round yesterday that was co-led by pharmaceutical firm Novo Holdings and investment firm Omega Funds.
Invus and EcoR1 Capital also contributed to the round, as did a range of unnamed, existing investors.
Founded in 2015, Morphic is developing therapies for fibrosis, vascular disorders and autoimmune diseases as well as immuno-oncology treatments. The drugs target integrins, protein receptors that control a wide range of cellular processes.
Morphic’s technology…